What is the significance of a Predetermined Change Control Plan (PCCP) for AI imaging software?

A PCCP outlines the types of modifications an AI/ML-enabled SaMD can undergo without requiring a new 510(k) submission, provided the changes fall within the pre-specified parameters. This plan facilitates more agile updates while maintaining regulatory compliance. The FDA encourages the use of PCCPs for these adaptive systems.

What cybersecurity considerations apply to AI imaging software?

AI imaging software must adhere to cybersecurity principles to protect patient data and ensure device functionality. This includes implementing robust access controls, encryption, vulnerability management, and ensuring the integrity and authenticity of AI models and their outputs, as outlined in FDA cybersecurity guidance.

Is clinical validation required for AI imaging software?

Yes, clinical validation is crucial to demonstrate that the AI imaging software performs as intended in a clinical setting and provides accurate and reliable results. This involves rigorous testing with clinical data to support safety and effectiveness claims, aligning with requirements from bodies like the FDA and under the EU MDR.

All terms

Market SegmentsAI / ML in Devices Software Lifecycle Strategic Landscape

AI Imaging Software

Software that analyzes medical images to triage, detect, or quantify disease.

Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed May 5, 2026

Definition

AI imaging software uses deep learning to detect findings (intracranial hemorrhage, large-vessel occlusion, pulmonary embolism, lung nodules), quantify disease burden (LVO, ejection fraction, breast density), or triage worklists. Many AI imaging tools are cleared through 510(k) for triage, detection or quantification. FDA's list of AI-enabled devices shows radiology as the largest category. Predetermined change control plans let some products update models within agreed limits.

What the regulation says

AI imaging software, as a type of Medical Device Software (MDSW), is subject to regulatory oversight by bodies like the FDA in the United States and under the EU Medical Device Regulation (MDR). Regulators classify these devices based on their risk to patients, influencing the conformity assessment routes and pre-market submission requirements. For instance, the FDA provides guidance on Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) to clarify expectations for these adaptive systems.

What this means in practice

Cleared as SaMD; commercial success depends on hospital workflow integration, PACS connectivity, and dedicated reimbursement (NTAP, Category III CPT). Growing Predetermined Change Control Plan (PCCP) adoption for model updates.

Examples

An AI imaging software cleared to detect intracranial hemorrhage on CT scans must demonstrate its accuracy and reliability through clinical validation studies, aligning with FDA guidance on SaMD.
A manufacturer implements a Predetermined Change Control Plan (PCCP) for its AI software that quantifies ejection fraction, allowing for pre-approved updates to the model's training data without requiring a new 510(k).
A hospital integrates an AI breast density quantification tool into its PACS system, ensuring compliance with HIPAA for patient data privacy and cybersecurity standards for software integration.

Common pitfalls

•A common pitfall is failing to validate the AI algorithm on diverse, representative datasets, leading to biased performance and inaccurate diagnoses in real-world clinical populations.
•Another mistake is neglecting to establish robust post-market surveillance mechanisms to monitor the AI's performance drift and manage updates in a controlled manner.
•Some manufacturers underestimate the regulatory burden associated with modifications to AI models, especially when the changes impact the safety or effectiveness of the device.
•Assuming that a Predetermined Change Control Plan (PCCP) eliminates all regulatory submissions for AI model updates is incorrect; significant changes still require review.
•Not adequately addressing cybersecurity risks, such as data privacy breaches or malicious attacks on the AI model, can lead to patient harm and regulatory non-compliance.

Frequently asked questions

The classification of AI imaging software depends on its intended use and the level of risk it poses to patients. This can range from lower risk classifications, requiring less stringent oversight, to higher risk classifications, demanding extensive clinical evidence and regulatory review. For example, the FDA's risk-based framework for SaMD is a key determinant.

Grouped by theme

Editor's picks

· Hand-selected related concepts

Market Segments

Medical Imaging

Devices that produce images of the body for diagnosis or guidance.

Software & AI

Predetermined Change Control Plan(PCCP)

FDA mechanism to pre-authorize specific modifications to AI/ML-enabled devices.

Software & AI

Software as a Medical Device(SaMD)

Software intended for medical purposes that performs without being part of a hardware device.

More in Market Segments

· Same category

Market Segments

Aesthetic & Energy-Based Devices

Lasers, RF, ultrasound, cryolipolysis, and IPL systems used for medical and cosmetic indications, body contouring, hair removal, skin tightening, vascular lesions.

Market Segments

Cardiac Rhythm Management(CRM)

Implantable and external devices that monitor and treat cardiac arrhythmias, pacemakers, ICDs, CRT devices, and insertable cardiac monitors.

Market Segments

Cardiovascular Devices

Devices for diagnosing, monitoring, or treating cardiovascular disease.

Market Segments

Clinical Laboratory Improvement Amendments(CLIA)

U.S. federal standards that govern clinical laboratory testing.

Cited by

Where this term appears across MedTech Terms.

Ecosystems (3)

Latest in MedTech

Sources

3 sources

Sources support the definition or relevant regulatory context, not necessarily every claim on this page. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

Tier 2Regulator guidance and consensus· 1Tier 4Trade press and expert commentary· 2

Link health: 3 verified· last checked 2026-06-20

FDA·1AdvaMed·1MedTech Europe·1

Inline markers like [1] jump to the matching reference above.

My progress

All terms0 / 513

Market Segments0 / 38

Saved on this device, and to your account when signed in. View studied terms

Full glossary

Browse all terms A to Z, each with a short definition.

On this term

Category: Market Segments
Sources: 3
Updated: 5/5/2026

Compare with another term

Learn in 60 seconds

Software that analyzes medical images to triage, detect, or quantify disease.

·Cleared as SaMD; commercial success depends on hospital workflow integration, PACS connectivity, and dedicated reimbursement (NTAP, Category III CPT).
·Growing Predetermined Change Control Plan (PCCP) adoption for model updates.
·Many AI imaging tools are cleared through 510(k) for triage, detection or quantification.

Remember this

Watch out: A common pitfall is failing to validate the AI algorithm on diverse, representative datasets, leading to biased performance and inaccurate diagnoses in real-world clinical populations.

Related terms

You may also need

Auto-suggested from Market Segments and shared keywords.

All Market Segments terms